18 related articles for article (PubMed ID: 38581732)
1. Ganoderic acid D attenuates gemcitabine resistance of triple-negative breast cancer cells by inhibiting glycolysis via HIF-1α destabilization.
Luo B; Song L; Chen L; Cai Y; Zhang M; Wang S
Phytomedicine; 2024 Jul; 129():155675. PubMed ID: 38678954
[TBL] [Abstract][Full Text] [Related]
2. Discovery of acetophenone/piperazin-2-one hybrids as selective anti-TNBC cancer agents by causing DNA damage.
Zhang ZJ; Liao YT; Wang W; Yang C; Li D; Shao LD
Bioorg Med Chem Lett; 2024 Aug; 108():129802. PubMed ID: 38777278
[TBL] [Abstract][Full Text] [Related]
3. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
4. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
[TBL] [Abstract][Full Text] [Related]
5. Platycodin D, a metabolite of Platycodin grandiflorum, inhibits highly metastatic MDA-MB-231 breast cancer growth in vitro and in vivo by targeting the MDM2 oncogene.
Kong Y; Lu ZL; Wang JJ; Zhou R; Guo J; Liu J; Sun HL; Wang H; Song W; Yang J; Xu HX
Oncol Rep; 2016 Sep; 36(3):1447-56. PubMed ID: 27432230
[TBL] [Abstract][Full Text] [Related]
6. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer.
Elkhalifa D; Siddique AB; Qusa M; Cyprian FS; El Sayed K; Alali F; Al Moustafa AE; Khalil A
Eur J Med Chem; 2020 Feb; 187():111954. PubMed ID: 31838326
[TBL] [Abstract][Full Text] [Related]
8. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract][Full Text] [Related]
9. MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.
Vicente ATS; Salvador JAR
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232374
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
